{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T18:00:35Z","timestamp":1755799235000,"version":"3.44.0"},"reference-count":29,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T00:00:00Z","timestamp":1755561600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Introduction<\/jats:title>\n<jats:p>The advent of anaplastic lymphoma kinase (ALK) inhibitors has revolutionized the treatment of ALK-rearranged malignancies, establishing these agents as vital components of precision oncology. Despite their proven efficacy in prolonging progression-free and overall survival, ALK inhibitors are associated with notable adverse events, particularly cardiopulmonary complications such as pleural and pericardial effusions.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>This study investigates the real-world prevalence and risk of these effusions associated with five ALK inhibitors, crizotinib, ceritinib, alectinib, brigatinib, and lorlatinib, through disproportionality analysis using the FAERS pharmacovigilance database.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>The data revealed elevated reporting odds ratios (RORs) for pleural and pericardial effusions, with notable variability among the agents. Crizotinib exhibited RORs of 7.76 (95% CI: 6.60\u20139.12) and 9.00 (95% CI: 7.10\u201311.41) for pleural and pericardial effusions, respectively. Ceritinib demonstrated RORs of 7.36 (95% CI: 5.16\u201310.50) and 10.80 (95% CI: 6.79\u201317.19), respectively. Alectinib showed lower RORs of 4.76 (95% CI: 3.80\u20135.97) and 6.67 (95% CI: 4.92\u20139.04). Brigatinib displayed elevated RORs of 8.70 (95% CI: 6.58\u201311.52) and 7.87 (95% CI: 4.95\u201312.51). Lorlatinib presented the highest risk, with RORs of 8.61 (95% CI: 6.72\u201311.02) and 12.57 (95% CI: 9.08\u201317.38).<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusions<\/jats:title>\n<jats:p>This study highlights the critical need for vigilant pharmacovigilance and a multidisciplinary approach to balance the oncologic benefits of ALK inhibitors against their cardiopulmonary risks. By enhancing awareness and fostering proactive management, these findings aim to support the safe and effective use of ALK inhibitors in treating ALK-rearranged malignancies.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0330630","type":"journal-article","created":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T17:26:56Z","timestamp":1755624416000},"page":"e0330630","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["A real-world pharmacovigilance analysis of ALK inhibitor-associated pleural and pericardial effusion using the FDA Adverse Events Reporting System (FAERS) database from 2013 to 2024"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4080-3030","authenticated-orcid":true,"given":"Connor","family":"Frey","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2025,8,19]]},"reference":[{"issue":"2","key":"pone.0330630.ref001","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.ctrv.2013.07.002","article-title":"ALK inhibitors in the treatment of advanced NSCLC","volume":"40","author":"C Gridelli","year":"2014","journal-title":"Cancer Treat Rev"},{"key":"pone.0330630.ref002","doi-asserted-by":"crossref","first-page":"557","DOI":"10.3389\/fonc.2018.00557","article-title":"ALK inhibitors in the treatment of ALK positive NSCLC","volume":"8","author":"M Khan","year":"2019","journal-title":"Front Oncol"},{"key":"pone.0330630.ref003","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13045-015-0122-8","article-title":"Novel ALK inhibitors in clinical use and development","volume":"8","author":"C Iragavarapu","year":"2015","journal-title":"J Hematol Oncol"},{"key":"pone.0330630.ref004","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.phrs.2017.01.007","article-title":"Anaplastic lymphoma kinase (ALK) inhibitors in the treatment of ALK-driven lung cancers","volume":"117","author":"R Jr Roskoski","year":"2017","journal-title":"Pharmacol Res"},{"issue":"1","key":"pone.0330630.ref005","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.phrs.2012.11.007","article-title":"Anaplastic lymphoma kinase (ALK): structure, oncogenic activation, and pharmacological inhibition","volume":"68","author":"R Jr Roskoski","year":"2013","journal-title":"Pharmacol Res"},{"issue":"18","key":"pone.0330630.ref006","doi-asserted-by":"crossref","first-page":"5609","DOI":"10.1158\/1078-0432.CCR-08-2762","article-title":"Inhibition of ALK signaling for cancer therapy","volume":"15","author":"YP Moss\u00e9","year":"2009","journal-title":"Clin Cancer Res"},{"key":"pone.0330630.ref007","doi-asserted-by":"crossref","first-page":"1361443","DOI":"10.3389\/fphar.2024.1361443","article-title":"Interstitial lung disease associated with ALK inhibitors and risk factors: an updated comparative pharmacovigilance analysis","volume":"15","author":"J Dong","year":"2024","journal-title":"Front Pharmacol"},{"issue":"2","key":"pone.0330630.ref008","doi-asserted-by":"crossref","DOI":"10.1016\/j.cllc.2017.10.008","article-title":"Lung toxicity in non-small-cell lung cancer patients exposed to ALK inhibitors: report of a peculiar case and systematic review of the literature","volume":"19","author":"B Pellegrino","year":"2018","journal-title":"Clin Lung Cancer"},{"issue":"1","key":"pone.0330630.ref009","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jaccao.2022.09.006","article-title":"Cardiac toxicity of alectinib in patients with ALK+ lung cancer","volume":"5","author":"MA Pruis","year":"2023","journal-title":"JACC CardioOncol"},{"issue":"7","key":"pone.0330630.ref010","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1080\/14740338.2023.2182284","article-title":"Risks of cardiovascular toxicities associated with ALK tyrosine kinase inhibitors in patients with non-small-cell lung cancer: a meta-analysis of randomized control trials","volume":"22","author":"J Zhao","year":"2023","journal-title":"Expert Opin Drug Saf"},{"issue":"11","key":"pone.0330630.ref011","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1080\/14740338.2023.2234279","article-title":"Cardiac arrhythmias associated with anaplastic lymphoma kinase (ALK) inhibitors: an analysis of the FDA Adverse Event Reporting System (FAERS)","volume":"22","author":"F Wang","year":"2023","journal-title":"Expert Opin Drug Saf"},{"key":"pone.0330630.ref012","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2147\/OAEM.S29942","article-title":"Pleural effusion: diagnosis, treatment, and management","volume":"4","author":"VS Karkhanis","year":"2012","journal-title":"Open Access Emerg Med"},{"key":"pone.0330630.ref013","first-page":"104142","article-title":"Diagnosis, treatment, and management of pericardial effusion- review","volume":"80","author":"N Yamani","year":"2022","journal-title":"Ann Med Surg (Lond)"},{"issue":"1","key":"pone.0330630.ref014","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/pharma4010001","article-title":"Hepatobiliary adverse events associated with pembrolizumab: a pharmacovigilance study from the FDA Adverse Event Reporting System (FAERS) database","volume":"4","author":"C Frey","year":"2024","journal-title":"Pharmacoepidemiology"},{"issue":"3","key":"pone.0330630.ref015","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3390\/antib13030059","article-title":"Adverse events of PD-1, PD-L1, CTLA-4, and LAG-3 immune checkpoint inhibitors: an analysis of the FDA adverse events database","volume":"13","author":"C Frey","year":"2024","journal-title":"Antibodies (Basel)"},{"issue":"10","key":"pone.0330630.ref016","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1158\/2159-8290.CD-16-0596","article-title":"Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer","volume":"6","author":"JF Gainor","year":"2016","journal-title":"Cancer Discov"},{"issue":"1","key":"pone.0330630.ref017","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1186\/s12885-024-11916-4","article-title":"Identifying optimal ALK inhibitors in first- and second-line treatment of patients with advanced ALK-positive non-small-cell lung cancer: a systematic review and network meta-analysis","volume":"24","author":"M Zhao","year":"2024","journal-title":"BMC Cancer"},{"issue":"5","key":"pone.0330630.ref018","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1007\/s10637-018-0605-x","article-title":"Crizotinib-induced simultaneous multiple cardiac toxicities","volume":"36","author":"T Oyakawa","year":"2018","journal-title":"Invest New Drugs"},{"key":"pone.0330630.ref019","doi-asserted-by":"crossref","first-page":"858279","DOI":"10.3389\/fphar.2022.858279","article-title":"Anaplastic lymphoma kinase tyrosine kinase inhibitor-associated cardiotoxicity: a recent five-year pharmacovigilance study","volume":"13","author":"Y Liu","year":"2022","journal-title":"Front Pharmacol"},{"issue":"7","key":"pone.0330630.ref020","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1158\/1078-0432.CCR-19-3740","article-title":"Crizotinib in ROS1 and MET Deregulated NSCLC-Letter","volume":"26","author":"M Wiesweg","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"3","key":"pone.0330630.ref021","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.lungcan.2015.10.028","article-title":"Responses to the multitargeted MET\/ALK\/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation","volume":"90","author":"SE Jorge","year":"2015","journal-title":"Lung Cancer"},{"issue":"3","key":"pone.0330630.ref022","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.cllc.2022.01.003","article-title":"Safety of met tyrosine kinase inhibitors in patients with MET Exon 14 skipping non-small cell lung cancer: a clinical review","volume":"23","author":"A Cortot","year":"2022","journal-title":"Clin Lung Cancer"},{"issue":"7","key":"pone.0330630.ref023","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1111\/1759-7714.13496","article-title":"A case of ROS1-rearranged lung adenocarcinoma exhibiting pleural effusion caused by crizotinib","volume":"11","author":"H Tachi","year":"2020","journal-title":"Thorac Cancer"},{"issue":"6","key":"pone.0330630.ref024","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1158\/2159-8290.CD-13-0846","article-title":"The ALK inhibitor ceritinib overcomes crizotinib resistance in non\u2013small cell lung cancer","volume":"4","author":"L Friboulet","year":"2014","journal-title":"Cancer Discovery"},{"issue":"12","key":"pone.0330630.ref025","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1038\/nchembio.2489","article-title":"Polypharmacology-based ceritinib repurposing using integrated functional proteomics","volume":"13","author":"BM Kuenzi","year":"2017","journal-title":"Nat Chem Biol"},{"key":"pone.0330630.ref026","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2147\/CMAR.S129963","article-title":"The role of brigatinib in crizotinib-resistant non-small cell lung cancer","volume":"10","author":"L Mezquita","year":"2018","journal-title":"Cancer Manag Res"},{"issue":"16","key":"pone.0330630.ref027","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1200\/JCO.18.02236","article-title":"ALK resistance mutations and efficacy of lorlatinib in advanced anaplastic lymphoma kinase-positive non-small-cell lung cancer","volume":"37","author":"AT Shaw","year":"2019","journal-title":"J Clin Oncol"},{"key":"pone.0330630.ref028","first-page":"205","article-title":"Chapter 4 - Targeted therapy: small molecules.","volume-title":"Medicines for Cancer","author":"SK. De","year":"2023"},{"issue":"6","key":"pone.0330630.ref029","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s40264-023-01300-9","article-title":"Cardiovascular Toxicities Associated with Anaplastic Lymphoma Kinase Inhibitors: A Disproportionality Analysis of the WHO Pharmacovigilance Database (VigiBase)","volume":"46","author":"T Niimura","year":"2023","journal-title":"Drug Saf"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0330630","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T17:26:59Z","timestamp":1755624419000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0330630"}},"subtitle":[],"editor":[{"given":"Rajesh Kumar","family":"Singh","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2025,8,19]]},"references-count":29,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8,19]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0330630","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2025,8,19]]}}}